Tratamiento con eritropoyetina: Concepto y controversias

Sangre

Volumn 43, Issue 4, 1998, Pages 327-330

  Sans Mateu, Teresa ^a  

^a HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN;

ANEMIA; BLOOD AUTOTRANSFUSION; HEMATOCRIT; HEMODIALYSIS; HEMODILUTION; HUMAN; REVIEW; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION, AUTOLOGOUS; COST-BENEFIT ANALYSIS; ERYTHROPOIESIS; ERYTHROPOIETIN; HUMANS; PREOPERATIVE CARE; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT PROTEINS;

EID: 0031702753     PISSN: 00364355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Sawyer St, Krantz SB, Sawada K, Receptors for erythropoietin in mouse and human erythroid cells and placenta. Blood 1989; 74: 103-109.
2. Bachmann S, Le Hir M, Eckardt KU. Co-localization of erythropoietin mRNA and ecto5'-nucleotidase immunoreactivity in peritubular cells of rat renal cortex indicates that fibroblasts produce erythropoietin. J Histochem Cytochem 1993; 41: 335-341.
3. Jacobson LO, Goldwasser E, Fried W, Plzak L. Role of the kidney in erythropoiesis. Nature 1957; 179: 633-634.
4. Miyake T, Kung CKH, Goldwasser E. Purification of human erythropoietin. J Biol Chem 1977; 252: 5558-5564.
5. Lin F-K, Suggs S, Lin C-H, Browne JK, Smalling R, Egrie JC, et al. Cloning and expression of the human erythropoietic gene. Proc Natl Acad Sci USA 1985; 82: 7580-7584.
6. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM. Effect on human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986; 2: 1175-1178.
7. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: results of a combinend phase I and II clinical trial. N Engl J Med 1987; 316: 73-78.
8. Ludwig H, Fritz E, Kotzmann H, Hocker P, Gisslinger H, Barnas U. Erythropoietin treatment of anaemia associated with multiple myeloma. N Engl J Med 1990; 322: 1693-1699.
9. Fischl M, Galpin JE, Levine JD, Groopman JE, Henry DH, Kennedy P, et al. Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N Engl J Med 1990; 322: 1488-1493.
10. Widness JA, Veng-Pedersen P, Peters C, Pereira LM, Schmidt L, Lowe LS. Erythropoietin pharmacokinetics in premature infants:developmental, nonlinearity, and treatment effects. J Appl Physiol 1996; 80: 140-148.
11. Ward JW, Holmberg SD, Allen JR, Cohn DL, Critchley SE, Kleinman SH, et al. Transmission of human immunodeficiency virus (HIV) by blood transfusions screened as negative for HIV antibody. N Engl J Med 1988; 318: 473-478.
12. Alter HJ, Purcell RH, Shin JW, et al. Detection of antibody to hepatitis C virus in prospectively followed recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989; 321: 1494-1500.
13. Bofill C, Salas J, Vernis M, Surroca RM, Joven J. Evolución de la autotransfusión: influencia de la dieta y/o la ingesta de hierro. Sangre 1990; 35: 179-183.
14. Kampf D, Eckardt KU, Fisher HC, Schmalisch C, Ehmer B, Schostak M. Pharmacokinetics of recombinant human erythropoietin in dialysis patients after single and multiple subcutaneous administrations. Nephron 1992; 61: 393-398.
15. Salmonnson T, Danielson BG, Wikstrom B. The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects. Br J Clin Pharmac 1990; 29: 709-713.
16. Goodnough LT, Monk TG, Andriole GL. Erythropoietin therapy. N Engl J Med 1997; 13: 933-938.
17. Kruskall MS, Glazer EE, Leonard SS, Willson SC, Pacini DG, Donovan LM, et al. Utilization and effectiveness of a hospital autologous preoperative blood donor program. Transfusion 1986; 26: 335-340.
18. Wasman J, Goodnough LT. Autologous blood donation for elective surgery. JAMA 1987; 258: 3135-3137.
19. Renner SW, Howanitz PJ; Bachner P. Preoperative autologous blood donation in 612 hospitals. Arch Pathol Lab Med 1992; 116: 613-619.
20. Kickler TS, Spivak JL. Effect of repeated whole blood donations on serum immunoreactive erythropoietin levels in autologous donors. JAMA 1988; 260: 65-67.
21. Goodnough LT, Wasman J, Corlucci K, Chernossky A. Limitations to donating adequate autologous blood prior to elective orthopedic surgery. Arch Surg 1989; 124: 494-496.
22. Goodnough LT, Brittenham GM. Limitations of the erythropoietic response to serial phlebotomy: implications for autologous blood donor programs. J Lab Clin Med 1990; 115: 28-35.
23. Goodnough LT, Rudnick S, Price TH, et al. Increased preoperative collection of autologous blood with recombinant human erythropoietin therapy. N Engl J Med 1989; 321: 1163-1168.
24. Goodnough LT, Price TH, Friedman KD, Jhonston M, Ciavarella D, Khan N, et al. A phase III trial of recombinant human erythropoietin therapy in nonanemic orthopedic patients subjected to aggressive removal of blood for autologous use: dose, response, toxicity and efficacy. Transfusion 1994; 34: 66-71.
25. Beris P, Mermillod B, Levy G, Laubriat M, Soulier-Lauper M, Tullen E, et al. Recombinant human erythropoietin as adjuvant treatment for autologous blood donation. Vox Sang 1993; 65: 212-218.
26. Biesma DH, Malx JJ, Kraaijenhagen RJ, Franke W, Messinger D, van de Wiel A. Lower homologous blood requirement in autologous blood donation after treatment with recombinant human erythropoietin. Lancet 1994; 344: 367-370.
27. Hayashi J, Kumon K, Takanashi S, Kawashima Y, Eguchi S, Takatu F, et al. Subcutaneous administration of recombinant human erythropoietin before cardiac surgery: a double-blind, multicenter trial in Japan. Transfusion 1994; 34: 142-146.
28. Sans T, Bofill C, Joven J, Clivillé X, Simó JM, Llobet X, et al. Effectiveness of very low doses of subcutaneous recombinant human erythropoietin for autologous blood donation before orthopedic surgery. Transfusion 1996; 36: 29-36.
29. Mercuriali F, Zanella A, Barosi G, Inghilleri G, Biffi E, Vinci A, et al. Use of erythropoietin to increase the volume of autologous blood donated by orthopedic patients. Transfusion 1993; 33: 55-60.
30. Price TH, Goodnough LT, Vogler WR, Sacher RA, Hellman RM, Johnston MF, et al. The effect of recombinant human erythropoietin on the efficacy of autologous blood donation in patients with low hematocrit: A multicenter, randomized, double-blind, controlled trial. Transfusion 1996; 36: 29-36.
31. Mercuriali F, Gualtieri G, Sinigaglia L, Inghilleri G, Biffi E, Vinci A, et al. Use of recombinant human erythropoietin to assist autologous blood donation by anemic rheumatoid arthritis patients undergoing major orthopedic surgery. Transfusion 1994; 34: 501-506.
32. Monk TG, Goodnough LT, Andriole GL, Colberg JW, Lemon DJ, Martin KJ. Preoperative recombinant human erythropoietin therapy enhances the efficacy of acute normovolemic hemodilution. Anesth Analg 1995; 80: Suppl: S320. abstract.
33. Etchason J, Petz L, Keeler E, Calhoun L, Kleinsman S, Snider C, et al. The cost effectiveness of preoperative autologous blood donations. N Engl J Med 1995; 332: 719-724.
34. Birkmeyer JD, Goodnough LT, AuBuchon JP, Noordsij PG, Litenberg B. The costeffectiveness of preoperative autologous blood donation for total hip and knee replacement. Transfusion 1993; 33: 544-551.
35. Canadian orthopedic perioperative recombinant human erythropoietin study group. Effectiveness of perioperative recombinant human erythropoietin in elective hip replacement. The Lancet 1993; 341: 1227-1232.
36. Faris PM, Ritter MA, Abels RI and the American Erythropoictin Study Group. The effects of recombinant human erythropoietin on perioperative transfusion requirements in patients having a major orthopaedic operation. J Bone Joint Surg Am 1996; 78-A: 62-72.
37. Cohen JA, Brecher ME. Preoperative autologous blood donation: benefit or detriment? A mathematical analysis. Transfusion 1995; 35: 640-644.
38. McMahon FG, Vargas R, Ryan M, Jain Ak, Abels RI, Perry B, et al. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood 1990; 76: 1718-1222.
39. Besarab A, Flaharty KK, Erslev AJ, Mc Crea JB, Vlasses PM, Medina F, et al. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: The case for subcutaneous administration. J Am Soc Nephrol 1992; 2: 1405-1416.
40. Goldberg MA, McCutchen JW, Jove M, Di Cesare P, Friedman RJ, Poss R, et al. A safety and efficacy comparision study of two dosing regimens of epoetin alfa in patients undergoing major orthopedic surgery. Am J Orthop 1996; 25: 544-552.
41. Goodnough LT, Verbrugge D, Marcus RE, Goldberg V. The effect of patient size and dose of recombinant human erythropoietin therapy on red blood cell expansion in autologous blood phlebotomy with and without erythropoietin therapy. Transfusion 1992; 32: 441-445.
42. Chun TY, Martin S, Lepor H. Preoperative recombinant human erythropoietin injection versus preoperative autologous blood donation in patients undergoing radical retropubic prostatectomy. Urology 1997; 50: 727-732.